MX348611B - Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana. - Google Patents
Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.Info
- Publication number
- MX348611B MX348611B MX2012007735A MX2012007735A MX348611B MX 348611 B MX348611 B MX 348611B MX 2012007735 A MX2012007735 A MX 2012007735A MX 2012007735 A MX2012007735 A MX 2012007735A MX 348611 B MX348611 B MX 348611B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- treatment
- inflammatory bowel
- bowel disease
- prophylaxis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Abstract
La presente invención se refiere a una forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a infección bacteriana, en donde dicha forma de dosificación comprende: (i) un componente de liberación retardada comprendiendo una cantidad de antibiótico efectiva para reducir la colonización de bacterias patogénicas en el tracto gastrointestinal, comprendiendo dicho antibiótico una combinación de sulfametoxazol, y trimetoprim; y (ii) un componente de liberación inmediata que comprende una formulación de probióticos en una cantidad efectiva para restaurar las colonias de microflora normal en el intestino, en donde dicho componente de liberación inmediata libera dicha formulación de probióticos luego del contacto con el fluido en el estómago; y en donde dicho componente de liberación retardada libera dicho antibiótico a un pH de 7 o mayor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29147409P | 2009-12-31 | 2009-12-31 | |
PCT/US2010/062339 WO2011082218A1 (en) | 2009-12-31 | 2010-12-29 | Compositions and method for treatment and prophylaxis of inflammatory bowel disease |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012007735A MX2012007735A (es) | 2012-09-28 |
MX348611B true MX348611B (es) | 2017-06-21 |
Family
ID=44226799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012007735A MX348611B (es) | 2009-12-31 | 2010-12-29 | Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana. |
Country Status (7)
Country | Link |
---|---|
US (4) | US9138441B2 (es) |
EP (1) | EP2519108A4 (es) |
AU (1) | AU2010339573B2 (es) |
CA (1) | CA2785658C (es) |
IL (1) | IL220613B (es) |
MX (1) | MX348611B (es) |
WO (1) | WO2011082218A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010339573B2 (en) | 2009-12-31 | 2014-08-28 | Ira Milton Trachtman | Compositions and method for treatment and prophylaxis of inflammatory bowel disease |
US20120094931A1 (en) * | 2010-06-30 | 2012-04-19 | Collins Colm | Compositions and methods to modulate progression and onset of inflammatory bowel disease |
US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
WO2013036290A1 (en) * | 2011-09-09 | 2013-03-14 | Yale University | Compositions and methods for assessing and treating inflammatory diseases and disorders |
CN103082292B (zh) * | 2011-11-02 | 2015-03-04 | 深圳华大基因研究院 | 罗斯氏菌(Roseburia)在治疗和预防肥胖相关疾病中的应用 |
WO2014011233A1 (en) * | 2012-07-09 | 2014-01-16 | Trachtman Ira Milton | Compositions and method for treatment and prophylaxis of inflammatory bowel disease |
SE1251123A1 (sv) * | 2012-10-05 | 2014-04-06 | Indevex Ab Publ | Födoämnesprodukt |
US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
DK3628161T3 (da) * | 2012-11-23 | 2023-05-30 | Seres Therapeutics Inc | Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf |
US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
WO2014121304A1 (en) | 2013-02-04 | 2014-08-07 | Seres Health, Inc. | Compositions and methods |
JP2016509003A (ja) | 2013-02-04 | 2016-03-24 | セレス セラピューティクス インコーポレイテッド | 組成物および方法 |
JP2016519664A (ja) | 2013-03-15 | 2016-07-07 | セレス セラピューティクス インコーポレイテッド | ネットワークを基にした微生物組成物及び方法 |
EP3049070A4 (en) * | 2013-09-27 | 2017-04-05 | Ira Milton Trachtman | Compositions and methods for treatment and prophylaxis of gastrointestinal diseases |
KR102515850B1 (ko) | 2013-11-25 | 2023-03-30 | 세레스 테라퓨틱스, 인코포레이티드 | 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도 |
US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
US9956282B2 (en) | 2013-12-16 | 2018-05-01 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
AU2015284425B2 (en) | 2014-07-01 | 2021-04-01 | Probi USA, Inc. | Bi-layer dual release probiotic tablets |
US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
JP2018507872A (ja) * | 2015-03-09 | 2018-03-22 | バイオイミュナイザー・ソチエタ・ア・ガランツィア・リミタータBioimmunizer SAGL | ビフィズス菌およびプロバイオティクスから単離された細胞壁をともなう抗酸化剤の組み合わせを含むアンチエイジング組成物 |
AU2018318132A1 (en) | 2017-08-14 | 2020-02-27 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
CN109170163A (zh) * | 2018-09-29 | 2019-01-11 | 华南农业大学 | 一种含有纳豆芽孢杆菌的高效饲料添加剂 |
US11813296B2 (en) * | 2018-10-04 | 2023-11-14 | Deerland Enzymes, Inc. | Bacillus subtilis probiotics and methods of use for improving immune function, hormonal status, and physical performance |
CA3124725A1 (en) * | 2018-10-10 | 2020-04-16 | Servatus Ltd | Methods of treatment of inflammatory conditions and associated infections |
CN114225024B (zh) * | 2021-12-29 | 2022-08-19 | 山东健袖生态科技有限公司 | 一种用于治疗疾病的益生菌药物 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6461607B1 (en) | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
IL143632A0 (en) | 1998-12-11 | 2002-04-21 | Urex Biotech Inc | Pharmaceutical compositions containing lactobacillus |
US8048924B2 (en) * | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
IL152127A0 (en) | 2002-10-06 | 2003-05-29 | Bio Balance Corp | Probiotic compositions for the treatment of inflammatory bowel disease |
AU2003303894A1 (en) * | 2003-01-30 | 2004-08-30 | The Regents Of The University Of California | Inactivated probiotic bacteria and methods of use thereof |
HUE027757T2 (en) * | 2004-05-14 | 2016-11-28 | Merck Sharp & Dohme | Treatment of diseases associated with the use of antibiotics |
DK3067057T3 (da) * | 2005-09-28 | 2023-02-13 | Nordic Rebalance As | Probiotisk fermenteret cerealiesammensætninger til anvendelse ved behandling af gastrointestinale lidelser forårsaget af pro-inflammatoriske bakterier |
EP1993384A2 (en) * | 2006-01-11 | 2008-11-26 | Attune Foods | Probiotic food, process for its preparation and dietary regimen |
US20070298018A1 (en) * | 2006-06-23 | 2007-12-27 | Lacpro Industries, Llc | Novel lactobacillus bulgaricus strain and compositions |
JP5140154B2 (ja) | 2007-06-27 | 2013-02-06 | アストラゼネカ・アクチエボラーグ | ピラジノン誘導体および肺疾患の処置におけるそれらの使用 |
US20090098088A1 (en) * | 2007-10-10 | 2009-04-16 | The Procter & Gamble Company | Methods And Kits For The Treatment Of Diverticular Conditions |
WO2009092810A2 (en) * | 2008-01-24 | 2009-07-30 | Bacterfield Oü | Single pharmaceutical composition containing antibiotics and probiotics |
RU2010143460A (ru) | 2008-05-01 | 2012-06-10 | Дзе Проктер Энд Гэмбл Компани (US) | Способы и наборы для терапии восстановительных состояний кишечника |
WO2009158384A1 (en) * | 2008-06-27 | 2009-12-30 | The Procter & Gamble Company | Methods and kits for the treatment inhibition, and maintenance of gastrointestinal disorders |
EP2485742A4 (en) * | 2009-10-06 | 2013-03-20 | Scott Dorfner | ANTIBIOTIC FORMULATIONS WITH REDUCED SIDE EFFECTS ON STOMACH AND DARM |
RU2012121599A (ru) | 2009-10-27 | 2013-12-10 | Люпин Лимитед | Твердая дисперсия рифаксимина |
AU2010339573B2 (en) | 2009-12-31 | 2014-08-28 | Ira Milton Trachtman | Compositions and method for treatment and prophylaxis of inflammatory bowel disease |
-
2010
- 2010-12-29 AU AU2010339573A patent/AU2010339573B2/en not_active Ceased
- 2010-12-29 MX MX2012007735A patent/MX348611B/es active IP Right Grant
- 2010-12-29 CA CA2785658A patent/CA2785658C/en not_active Expired - Fee Related
- 2010-12-29 WO PCT/US2010/062339 patent/WO2011082218A1/en active Application Filing
- 2010-12-29 EP EP10841670.2A patent/EP2519108A4/en not_active Withdrawn
- 2010-12-29 US US13/517,486 patent/US9138441B2/en not_active Expired - Fee Related
-
2012
- 2012-06-24 IL IL220613A patent/IL220613B/en active IP Right Grant
-
2015
- 2015-09-18 US US14/857,933 patent/US9492488B2/en not_active Expired - Fee Related
-
2016
- 2016-10-13 US US15/292,300 patent/US9649348B2/en active Active
-
2017
- 2017-05-11 US US15/592,786 patent/US20170246226A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2785658A1 (en) | 2011-07-07 |
IL220613B (en) | 2018-06-28 |
CA2785658C (en) | 2017-10-24 |
US20120276201A1 (en) | 2012-11-01 |
EP2519108A1 (en) | 2012-11-07 |
MX2012007735A (es) | 2012-09-28 |
US20160000839A1 (en) | 2016-01-07 |
US9492488B2 (en) | 2016-11-15 |
US20170246226A1 (en) | 2017-08-31 |
EP2519108A4 (en) | 2013-10-16 |
WO2011082218A1 (en) | 2011-07-07 |
US20170056456A1 (en) | 2017-03-02 |
US9138441B2 (en) | 2015-09-22 |
AU2010339573B2 (en) | 2014-08-28 |
IL220613A0 (en) | 2012-08-30 |
US9649348B2 (en) | 2017-05-16 |
AU2010339573A1 (en) | 2012-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX348611B (es) | Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana. | |
WO2015047941A3 (en) | Compositions and methods for treatment and prophylaxis of gastrointestinal diseases | |
WO2014011564A3 (en) | Compositions and method for treatment and prophylaxis of inflammatory bowel disease | |
HRP20160598T1 (hr) | Bakterijski sastavi za prevenciju i liječenje degenerativne bolesti | |
MY148872A (en) | Use of bifidobacterium longum for the prevention and treatment of inflammation | |
MX2019009132A (es) | Composiciones bacterianas sinergicas y sus metodos de produccion y usos. | |
EP3904502A3 (en) | Compositions and methods | |
IN2012DN01638A (es) | ||
MX351670B (es) | Bacteria bacillus para uso en tratar y prevenir infecciones en animales acuaticos. | |
MX346335B (es) | Composiciones antisentido, y metodos para obtener y usar las mismas. | |
ZA201207377B (en) | Composition comprising probiotic bacteria for use in the treatment of immune disorders | |
PL2249824T3 (pl) | Laktylany w zapobieganiu i leczeniu infekcji wywoływanych bakteriami gram-dodatnimi u zwierząt | |
MY146595A (en) | Probiotic bifidobacterium strains | |
MY162344A (en) | Probiotic composition for use in the treatment of bowel inflammation | |
MY189329A (en) | Mixture of non-digestible oligosaccharides for stimulating the immune system | |
PL3016667T3 (pl) | Probiotyczne szczepy bakteryjne do zapobiegania i leczenia chorób w jamie ustnej | |
MX2011005370A (es) | Formas de dosis orales de sufentanilo que comprenden agentes barredores de oxígeno y métodos de uso de los mismos. | |
IL225581B (en) | Defibrotide for use in the prevention and/or treatment of graft-versus-host disease (gvhd) | |
IL256966A (en) | Methods and compositions for the treatment of diseases related to the thyroid gland, with a reduced amount of folates | |
PL2457576T3 (pl) | Szczep Lactobacillus reuteri do stosowania medycznego i weterynaryjnego w profilaktyce oraz w leczeniu zespołu metabolicznego lub infekcji | |
HU0700745D0 (en) | Use of edta and its derivatives for the prevention and treatment of bacterial intestinal swine diseases and for enhancement of efficiency of antibiotics in curing such ilnesses | |
HUE042643T2 (hu) | Lactobacillus reuteri ATCC PTA 6475 csontveszteség | |
EP2373327A4 (en) | COMPOSITION WITH EXPRESSION OR ACTIVITY INHIBITORS OF NINJURIN 1 FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES | |
MX2013013339A (es) | Uso de secnidazol en el tratamiento de infecciones dentales. | |
MY193625A (en) | Probiotic composition for treatment or prevention of high blood cholesterol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |